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Volodymyr SerhiioVych moSiienko 
(1934–2017)
Professor Volodymyr Serhiiovych Mosiienko, the scientist, the leading researcher, Doctor of Medicine passed away
 
V o l o d y m y r  M o -
si ienko was born 
o n  Fe b r u a r y  2 3 , 
1934 in Zinkiv village 
Poltava region in the 
fa mily of the peas-
ants. Upon graduat-
ing from the second-
ary school, he stud-
ied at the general 
medical department 
of O.O. Bogomo-
lets Kyiv Medical 
Institute. As a quali-
fied M.D., Dr. Mo-
s i i e n k o  w o r k e d 
as a general practitioner for two years. Having heard 
the news that the research oncological institute was 
to set up in Kyiv, Dr. Mosiienko decided to take the path 
of studies in such a difficult and intriguing field. Dr. Mo-
siienko started his career of researcher as the post-
graduate under the supervision of Prof. R.E. Kavetsky, 
the famous Ukrainian scientist. In 1965, Dr. Mosiienko 
defended his PhD thesis “Development of the method 
for pelvic perfusion and its use for the treatment 
of the experimental malignant tumors”. At that time, 
the regional perfusion was considered as one of the 
promising approaches for cancer thera py. And later 
on, Dr. Mosiienko applied successfully the method 
of the regional perfusion in the clinics.
Dr. Mosiienko has contributed much into the 
research in the field of pharmacodynamics and 
pharmacokinetics of anticancer drugs. The study 
of oxygen metabolism, the structured water, and 
blood microcirculation in the healthy and malignant 
tissues were among the fields of his scientific interests. 
He has developed the novel approaches for the use 
of antihypoxants, normo- and hypobaric hypoxia and 
cryogenic surgery aimed at increasing the efficacy 
of cancer treatment.
In 1973, Dr. Mosiienko defended his doctoral thesis 
“Regional perfusion in the treatment of malignan-
cies (experimental-and-clinical study)”. Academi-
cian R.E. Kavetsky was the research adviser of both 
his PhD and doctoral theses.
Dr. Mosiienko devoted considerable efforts 
to elucidate the role of oxygen and free radicals in the 
development of tumor. In particular, he studied the ef-
fects of the increased or decreased oxygen pressure 
on tumor growth. Dr. Mosiienko explored how to use 
the reactive oxygen species both alone and in complex 
with cytostatics for cancer treatment. He suggested 
that the hypoxic state of the tissues in tumor-bearing 
host represents the adaptive response contributing 
to increasing survival of cancer patients. Therefore, 
contrary to the wide-spread belief that hypoxic treat-
ment is much like “drive out fire with fire”, Dr. Mosiienko 
put forward the idea that hypoxic treatment in fact 
should be considered as the placement of the host 
into more adequate setting approaching the patient 
to the “physiological rest state” sparing the energy 
resources and deteriorating the environment for tumor 
cell growth.
In recent years, Dr. Mosiienko became enthusi-
astic in developing the novel research area — study 
of nanoparticles as the probable innovative approach 
for cancer treatment. He obtained important results 
in experiments with silicon oxide nanoparticles and 
fullerenes suggesting the original approaches in the-
rapy of cancer patients.
Dr. Mosiienko is coauthor of the development 
of the domestic immunomodulator Blasten. The drug 
is regis tered in Ukraine and applied in the clinical set-
tings. Dr. Mosiienko also was engaged in the studies 
aimed at improving the efficacy of anticancer vaccines.
Dr. Mosiienko authored more than 200 scientific 
papers and 4 monographs. He has 10 patents for his 
inventions. He supervised seven completed PhD the-
ses. In his last monographs “Integral Approach towards 
Therapy of Neoplastic Diseases” (2009) and “Cancer: 
Path into Unknown, Disappointments and Hopes” 
(2010), Dr. Mosiienko attempted to consider cancer 
problem in the light of the complex interrelationships 
in the “host — tumor — environment” triad. In this view, 
the author suggested and substantiated the novel ap-
proach to cancer treatment that he called as integral 
(adaptive) therapy. Unfortunately, the untimely death 
prevented him from finishing these studies.
Dr. Mosiienko was generous and modest re-
sponding to the needs of others. The bright memory 
of Volodymyr Serhiiovych Mosiienko will live forever 
in the hearts of all who knew him.
Administration and team 
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